Healthcare and Life Sciences
The Indonesian healthcare system is a dynamic and evolving landscape, characterised by a complex interplay of factors ranging from government policies and healthcare infrastructure to the diverse healthcare needs of its vast population. As a continuosly expanding industry, the Indonesian healthcare sector is not only challenging but also of significant importance and interest in Southeast Asia.
To meet these demands, we provide unparalleled solutions for a wide range of healthcare matters. At the core of our strength is an experienced team renowned for offering expert advice to a diverse array of healthcare entities. Our list of clients includes hospitals, pharmaceutical companies, medical laboratories, medical device manufacturers, medical technology firms, and players in the life sciences industry. Our extensive experience and expertise in these sectors have attracted clients seeking legal counsel for various needs, including hospital restructurings, domestic and global acquisitions, strategic investments, IPOs, and advisory services related to healthcare infrastructure.
Furthermore, one of our key strengths emanates from our renowned M&A practice, which works closely in conjunction with our Healthcare and Life Sciences practice. Together, we blend business acumen and healthcare regulatory insight to keep our clients consistently in the lead. By integrating this specialised knowledge with overarching legal expertise, we provide an unrivaled level of support and advocacy.
Hospitals:
- Advised Columbia Asia Hospitals Group and PT Nusautama Medicalindo in relation to the proposed restructuring of Columbia Asia Hospitals in Indonesia, including legal advice, preparation and review on transaction documents and assistance on the BKPM process.
- Advised Warburg Pincus Singapore in its investment in Hermina Hospital group.
Pharmaceuticals:
- Advised Kalbe in the 100% share acquisition of PT Aventis Pharma from Sanofi Aventis Participations, Hoechst GmbH, dan PT Usaha Minidin Raya. PT Aventis Pharma is a Sanofi’s Indonesian subsidiary that runs pharmaceutical business activities.
- Advised Kalbe in the sale of a minority stake in Indonesia-based Kalbe Genexine Biologics (“KGBio”), a leading integrated biologic holding company focused on the in-licensing, clinical development, and manufacturing of novel biologicals and biosimilar molecules, to General Atlantic, global private equity firm, amounted to USD 55 million. General Atlantic’s investment will support KGBio’s ongoing clinical development, asset acquisition plan, and production capacity expansion efforts.
- Represented PT Soho Global Health Tbk., an Indonesian leading healthcare company, on its IPO. The company offered 114,380,700 shares or 13.78% of its total issued and paid-up capital. The shares are listed on the Indonesia Stock Exchange. Our M&A team advised Quadria Capital, as the holder of convertible bonds, in converting its bonds in conjunction with this IPO process.
Medical Laboratory:
- Represented PT Genomik Solidaritas Indonesia on the establishment of GSI Lab, the first high throughput lab in Indonesia that can perform Polymerase Chain Reaction (PCR) tests.
Medical Devices:
- Acted as the Indonesian legal counsel to One Med, an Indonesian-based medical devices manufacturer, in their initial public offering on 8 November 2022. The "One Med" brand is now one of the leading medical device brands in Indonesia.
Other Medical Technology:
- Assisted one of the largest natural resource companies in Indonesia in relation to its proposed joint venture with a US health technology company to provide AI-driven medical app to analyze billions of health events, which will then be used to recommend treatment to telemedical patients. AHP assisted in reviewing the SaaS License Agreement from an Indonesian legal perspective and the incorporation of the joint venture company in Indonesia.
Our commitment lies in delivering a comprehensive suite of integrated services crafted to ensure the success of domestic and cross-border M&A transactions. Our expertise extends to representing both national and multinational healthcare and life sciences companies and assisting clients, varying from the investor’s side and the business actors, in navigating the complexities of the healthcare landscape, facilitating transactions that transcend geographical boundaries.
Our team provides strategic guidance throughout every stage of the M&A process, ensuring a seamless and successful transaction. In the Corporate/M&A area, we go beyond the conventional approach, assisting healthcare service companies from inception to providing support for investments, restructuring, and divestment.
We offer a full spectrum of services tailored to your unique needs. We help our clients with:
- Corporate services
- Corporate regulatory advisory
- Foreign investments
- Commercial agreements
- Acquisitions and divestments of companies (both public and private), businesses and assets
- Mergers
- Takeovers
- Reverse Takeovers (RTOs)
- Delisting, privatizations
- Corporate restructuring
- Private equity investments
Key Contacts :
We bring a wealth of expertise to the intersection of the healthcare industry and capital markets. Our comprehensive range of integrated services is dedicated to navigating the intricacies of capital markets with a specific focus on the unique needs of the healthcare and life sciences sector.
Our team specialises in providing a full spectrum of services for various capital market transactions, including equity and debt offering, whether under domestic or global offering rules, pre-IPO investments, consent solicitations, and exchange offers of securities.
Our team possesses a deep understanding of the healthcare and life sciences industry, allowing us to tailor our services to meet your specific needs. From global offerings to compliance with regulatory standards, we provide end-to-end support to safeguard your interests in the capital market. With a history of successful transactions in the healthcare sector, we stand as a reliable partner in your journey through the complexities of capital markets.
We help clients with:
- Equity and debt offering
- IPOs
- Rights issuance
- Convertible instruments
- Employee stock options
- Tender offer
- Exchange offer
- Capital market compliance services
- Good Corporate Governance advisory
Key Contacts :
We recognise that success in the healthcare and life sciences industry goes hand-in-hand with meticulous adherence to regulatory standards. Our dedicated team of skilled lawyers and economists is committed to ensuring that your deals and operations not only meet but exceed compliance standards in the healthcare sector. We guide you through both pre- and post-deal requirements, providing comprehensive support tailored to the specific needs of healthcare and life sciences enterprises.
We believe that proactive antitrust and competition management is not just a legal requirement but a strategic advantage for healthcare excellence.
We help clients with:
- Merger review and notification
- Antitrust litigation
- Competition advisory
- Competition compliance program
- Competition audit
Key Contacts :
Awards & Accolades
- Medical and Healthcare Law Firm of the Year, ALB Indonesia Law Awards (2022)
- M&A – Tier I, IFLR1000 (2023)
- Corporate and M&A – Outstanding, Asialaw Profiles (2023)
- Corporate/M&A – Band 1, Chambers Asia Pacific (2024)
- Corporate and M&A – Tier 1, The Legal 500 (2023)
- M&A – Tier 1, ALB M&A Ranking (2023)
- Winner – Corporate & Commercial; M&A, Asia Business Law Journal Indonesia Law Firm Awards (2022)
Key Contact
